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Abstract
Introduction: We hypothesized that delirium symptoms may respond differently to antipsychotic therapy. The
purpose of this paper was to retrospectively compare duration and time to first resolution of individual delirium
symptoms from the database of a randomized, double-blind, placebo-controlled study comparing quetiapine (Q) or
placebo (P), both with haloperidol rescue, for critically ill patients with delirium.
Methods: Data for 10 delirium symptoms from the eight-domain, intensive care delirium screening checklist
(ICDSC) previously collected every 12 hours were extracted for 29 study patients. Data between the Q and P
groups were compared using a cut-off P-value of ≤0.10 for this exploratory study.
Results: Baseline ICDSC scores (5 (4 to 7) (Q) vs 5 (4 to 6)) (median, interquartile range (IQR)) and % of patients
with each ICDSC symptom were similar in the two groups (all P > 0.10). Among patients with the delirium
symptom at baseline, use of Q may lead to a shorter time (days) to first resolution of symptom fluctuation (4 (Q)
vs. 14, P = 0.004), inattention (3 vs. 8, P=.10) and disorientation (2 vs. 10, P = 0.10) but a longer time to first
resolution of agitation (3 vs. 1, P = 0.04) and hyperactivity (5 vs. 1, P = 0.07). Among all patients, Q-treated patients
tended to spend a smaller percent of time with inattention (47 (0 to 67) vs. 78 (43 to 100), P = 0.025),
hallucinations (0 (0 to 17) vs. 28 (0 to 43), P = 0.10) and symptom fluctuation (47 (19 to 67) vs. 89 (33 to 00), P =
0.04] and there was a trend for Q-treated patients to spend a greater percent of time at an appropriate level of
consciousness (26% (13 to 63%) vs. 14% (0 to 33%), P = 0.17].
Conclusions: Our exploratory analysis suggests that quetiapine may resolve several intensive care unit (ICU)
delirium symptoms faster than the placebo. Individual symptom resolution appears to differ in association with the
pharmacologic intervention (that is, P vs Q, both with as needed haloperidol). Future studies evaluating
antipsychotics in ICU patients with delirium should measure duration and resolution of individual delirium
symptoms and their relation to long-term outcomes.
Introduction
Delirium, characterized by acute disturbances of con-
sciousness and cognition that develop over a short time
in the context of an acute medical condition, occurs in
up to 50% of intensive care unit (ICU) patients [1,2].
Critically ill patients who develop delirium have a higher
mortality, a longer duration of mechanical ventilation
and may develop long-term cognitive abnormalities
[3-7]. The Intensive Care Delirium Screening Checklist
(ICDSC) is an eight-domain instrument that was specifi-
cally developed and validated for screening delirium in
ICU patients [8]. It has been shown to identify delirium
as well as psychiatrists using Diagnostic and Statistical
Method (DSM) IV criteria, to be highly reliable, to
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any medium, provided the original work is properly cited.improve the ability of both ICU physicians and nurses to
identify delirium in their patients and is supported by
formal pedagogical testing [8-13]. In contrast to binary
scales, such as the CAM-ICU, the presence of individual
delirium symptom features is an inherent part of the
diagnostic criteria [14]. In addition, the ICDSC can
identify subsyndromal delirium, a clinically important
syndrome that identifies patients that fall on a conti-
nuum between those with no neuropsychiatric symp-
t o m sa n dt h o s ew i t hD S MI V - d e f i n e dd e l i r i u m[ 1 5 - 1 8 ] .
Patients with subsyndromal delirium have a mortality
and length of stay that lies between normal patients and
those with delirium, and represents a cohort of patients
especially responsive to treatment measures for delirium.
Whether the administration of antipsychotic medica-
tions improves outcome of ICU patients with delirium
remains controversial [19]. Among the three published
pilot prospective, randomized trials (only two of which
have been placebo-controlled) that have evaluated antipsy-
chotic pharmacotherapy to prevent or treat delirium in
the ICU, only one small randomized, double-blind, pla-
cebo-controlled study has demonstrated benefit [20-22].
In this study, ICU patients with delirium who required the
administration of one or more doses of IV haloperidol
were randomized to either quetiapine or placebo, both
with as needed rescue therapy [20]. Quetiapine (up to 200
mg twice daily for a maximum of 10 days) was associated
with a shorter time to first resolution of delirium (1.0
(interquartile range (IQR), 0.5 to 3.0) vs. 4.5 days (IQR, 2.0
to 7.0; P = .001)) and a reduced duration of delirium (36
(IQR, 12 to 87) vs. 120 hrs (IQR, 60 to 195; P = .006))
[20]. In other studies, delayed treatment once delirium is
established has been reported as being associated with
worse outcomes [23]. Whether antipsychotic administra-
tion is beneficial for ICU delirium may depend on drug
choice, but may also vary with symptom constellation and
the effect of a given drug on specific symptoms (as has
been shown for delirium outside the ICU setting) [24,25].
The outcome of patients with delirium has been linked
to the particular delirium symptoms identified with
ICDSC evaluation [26]. However, no ICU delirium preven-
tion or treatment strategy published to date reports the
impact of interventions on time to resolution of individual
delirium symptoms [20-22,27-32]. We hypothesized that
the pattern of delirium symptom resolution would differ
between patients receiving quetiapine vs. placebo. In this
post-hoc analysis, we compared the delirium symptoms
evaluated by the ICDSC within our previous randomized
study in terms of the time to first resolution and the dura-
tion of each delirium symptom [20].
Materials and methods
Data for this IRB-approved, retrospective, post-hoc ana-
lysis is derived from a three-center, double-blind,
placebo-controlled study that evaluated the efficacy and
safety of quetiapine in adult ICU patients with delirium
(ICDSC ≥4), who had an order for as-needed haloperi-
dol and were tolerating enteral nutrition [20]. While
informed consent was obtained from all subjects in the
original study, the IRB did not require subjects to pro-
vide consent for their data to be used in this secondary
analysis given its post-hoc nature. During the study per-
iod 258 ICU patients were screened and 222 were
excluded. The exclusion criteria for this study were
extensive and included conditions that could mimic
delirium or place patients at increased risk for quetia-
pine-related adverse effects. Delirium assessments were
conducted every 8 to 12 hours by trained bedside nurses
using the ICDSC. All patients were managed with the
same as-needed intravenous haloperidol protocol. Ther-
apy (that is, quetiapine or a matching placebo) was
administered orally or via a nasogastric/enteral tube and
initiated at a dose of 50 mg every 12 hours. Therapy
was titrated upwards on a daily basis by increments of
50 mg every 12 hours to a maximum dose of 200 mg
every 12 hours if the subject received at least one dose
of as-needed haloperidol in the previous 24 hours. The
study drug was continued until one of the following
occurred: 1) the subject was deemed by the attending
intensivist (based on their clinical judgment) to no
longer demonstrate signs of delirium and, therefore, to
no longer require therapy with a scheduled antipsycho-
tic; 2) 10 days of therapy had elapsed; 3) ICU discharge
occurred; or 4) an adverse event potentially attributable
to the study drug occurred.
The ICDSC data were extracted from the study data-
base for subjects with more than half of the every-12-
hour ICDSC assessments completed in full during
blinded study drug administration. If more than one
ICDSC score was available for each 12-hour study per-
iod, the ICDSC with the highest score was used. While
the ICDSC evaluates eight different domains associated
with delirium, it actually evaluates 10 different delirium
symptoms [8]. Data from ICDSC domain #1 (level of
consciousness) evaluates both agitation and decreased
level of consciousness and ICDSC domain #5 (motor
activity) evaluates both hyperactivity and hypoactivity.
Therefore, these four symptoms for domains #1 and #5
were collected with the single symptoms from the other
six domains, resulting in 10 different symptoms of delir-
ium being evaluated.
The prevalence of each delirium symptom present at
the study baseline was compared between the quetiapine
and placebo groups using Pearson’s chi-square tests.
Among subsets of patients with each symptom at base-
line, the proportion experiencing symptom resolution
was compared between groups using Pearson’sc h i -
square tests. Because not all patients with symptoms
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curves were generated and used to compare the time to
first symptom resolution between groups. Among all
study patients, for each symptom, the median time to
first resolution for each group (that is, quetiapine versus
placebo) was estimated from the Kaplan-Meier curves
and the Log-rank test was used to compare the curves
between the two groups. For each patient the proportion
of time that each symptom was present was calculated.
Additionally, the percent time when patients were at an
appropriate level of consciousness was determined by
subtracting the sum of (agitation plus decreased level of
consciousness) from 1. Because the distribution of these
proportions tended to be skewed, a nonparametric Wil-
coxon rank sum test was used to compare the distribu-
tions between the quetiapine and placebo groups and
data were summarized as medians and interquartile
ranges (25th to 75th percentiles).
Given these were exploratory analyses and the fact
that the original trial was not designed or powered to
find associations with individual symptoms, we selected
an alpha of P ≤0.10 as our threshold for concluding sta-
tistical significance. While this higher threshold is more
likely to find between-group differences when none exist
(1/10 chance) when compared to the 1/20 chance when
P < 0.05 is used, it is also more likely to find a signifi-
cant association when one does exist, reducing type II
errors. No adjustments to P-values for multiple compar-
isons were made given the exploratory nature of this
study and unadjusted P-values for every comparison
done are presented in tables.
Results
Acceptable data for the analysis of ICDSC delirium
symptoms during blinded study drug administration
were available for 29 of the 36 patients enrolled in the
parent pilot study which required a diagnosis of delir-
ium for enrollment (quetiapine; n = 14; placebo; n =
15). The information on the first seven patients enrolled
at one of the study sites included only the ICDSC total
score and the detailed individual symptoms were not
available for this post-hoc analysis. All 29 other patients
had at least 50% complete symptom data recorded and
were included in this retrospective study. Overall, 16%
of all possible ICDSC symptom data-points were not
able to be assessed. Excessive sedation and inattention
were the most common reasons for not assessing all
ICDSC symptoms during the ICDSC assessments
included in the analysis. Baseline age, gender, Acute
Physiology and Chronic Health Evaluation (APACHE) II
score and proportion of patients intubated were similar
between each post-hoc group and the similar group in
the parent study. At baseline, neither the ICDSC score
(5 (4 to 6) (quetiapine) versus 5 (4 to 6); P = 0.32)) nor
the incidence of each delirium symptom was different
between the two groups (Table 1).
Among patients with the delirium symptom at base-
line, use of quetiapine may lead to a shorter time to
first resolution of symptom fluctuation (4 (quetiapine)
vs. 14 days, P = 0.004), inattention (3 vs. 8 days, P =
0.10) and disorientation (2 vs.10 days, P =0 . 1 0 ) ,b u ta
longer time to resolution of agitation (3 (quetiapine) vs.
1d a y s ,P = 0.04) and hyperactivity (5 vs. 1 days, P <
0.04) (Table 2). Among all patients, quetiapine-treated
patients tended to spend less percentage of time with
inattention (47 (0 to 67) vs. 78 (43 to 100), P = 0.025],
hallucinations (0 (0 to 17) vs. 28 (0 to 43), P = 0.10) and
symptom fluctuation (47 (19 to 67) vs. 89 (33 to 100), P
= 0.04) and there was a trend for quetiapine-treated
patients to spend more percentage of time at an appro-
priate level of consciousness (26 (13 to 63) vs. 14 (0 to
33), P = 0.17) (Table 3).
Discussion
Recent investigations in both ICU and non-ICU popula-
tions have expanded the classification of patients with
delirium from a dichotomous clinical diagnosis of delir-
ium (that is, delirium or not), and focused instead on
specific components of delirium, recognizing the hetero-
geneity of patients with this complex syndrome [15,16].
Recent data highlights the importance that individual
symptom recognition and monitoring can have when
managing delirium [33]. Individual delirium symptoms
can be screened in ICU patients using a tool such as the
ICDSC. Each delirium symptom evaluated with the
ICDSC is highly discriminatory when distinguishing
between critically ill patients with or without delirium,
and after adjustment for severity of illness and coma,
specific symptoms of delirium independently predict
mortality in sub-syndromal delirium [26].
Table 1 Prevalence of delirium symptoms evaluated by
the ICDSC at study baseline
Delirium symptons derived from
ICSDC
Quetiapine
(n = 14)
N (%)
Placebo
(n = 15)
N (%)
P-
value
Agitation 5 (35.7) 6 (40.0) 0.81
Decreased level of consciousness 6 (42.9) 6 (40.0) 0.88
Inattention 13 (92.9) 15
(100.0)
0.29
Disorientation 13 (92.9) 11 (84.6) 0.49
Hallucinations/Delusions 2 (14.3) 1 (6.7) 1.00
Hyperactivity 5 (35.7) 6 (40.0) 0.81
Hypoactivity 9 (64.3) 9 (60.0) 0.81
Inappropriate speech or mood 7 (77.8) 3 (42.9) 0.15
Sleep/wake cycle disturbances 8 (66.7) 10 (71.4) 0.79
Symptom fluctuation 11 (91.7) 13 (86.7) 0.68
ICDSC, Intensive Care Delirium Screening Checklist
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individual delirium symptoms to antipsychotic therapy
in the ICU and suggests that quetiapine use is associated
with more rapid resolution of many common ICU delir-
ium symptoms when compared to a placebo, resulting
in less time affected by hallucinations, inattention,
symptom fluctuation and potentially less time at an
undesirable level of consciousness. Although time to
first resolution of agitation and hyperactivity was longer
in patients receiving quetiapine, there appeared to be
more time spent in a state other than agitation or psy-
chomotor slowing, suggesting greater “normalcy” and
symptom control. It remains unclear. However, with agi-
tation and hyperactivity providing clinicians with the
greatest challenge when caring for a patient with
delirium and likely leading to the administration of
additional sedatives or antipsychotic medications further
research is needed to carefully evaluate this potential
effect. While the relative sedating effects of haloperidol
versus quetiapine are not well quantified, if haloperidol
has the greater sedative effect, the fact that nearly twice
as much “as needed” haloperidol was administered on
average to the placebo group may also account for the
faster resolution of agitation in this group. Identifying
which symptoms are most important regarding long-
term outcomes, and how best to describe their presence
or absence, will require further study. Despite the well-
established sedating properties of quetiapine, sleep-wake
cycle abnormalities were not improved in this small
sample of patients, suggesting sleep abnormalities
Table 2 Proportion of patients experiencing resolution and time to first resolution for the delirium symptoms
A
Resolved during therapy
A N (%) Time to first resolution
A
(hours; median (IQR))
Delirium symptoms derived from ICDSC Quetiapine
(n = 14)
Placebo
(n = 15)
BP-value Quetiapine
(n = 14)
Placebo
(n = 15)
CP-value
Agitation 5 (100.0) 6 (100.0) - 84 (48 to 204) 36 (24 to 60) 0.07
Decreased level of consciousness 5 (83.3) 6 (100.0) 0.30 36 (24 to 72) 24 (12 to 96) 0.78
Inattention 12 (92.3) 11 (73.3) 0.19 84 (24 to 168) 180 (72 to 240) 0.12
Disorientation 11 (85.6) 8 (72.7) 0.47 48 (12 to 216) 204 (36 to 240) 0.10
Hallucinations/delusions 2 (100.0) 1 (100.0) - 48 (24 to 72) 156 (144 to 156) 0.22
Hyperactivity 5 (100.0) 6 (100.0) - 120(60 to 192) 24 (12 to 48) 0.04
Hypoactivity 7 (77.8) 6 (66.7) 0.60 72 (48 to 132) 168 (96 to ne) 0.17
Inappropriate speech or mood 6 (85.7) 3 (100.0) 0.49 132(60 to 192) 72 (24 to 168) 0.31
Sleep/wake cycle disturbance 5 (62.5) 6 (60.0) 0.91 192 (24 to ne) 228 (144 to 240) 0.36
Symptom fluctuation 11 (100.0) 7 (53.8) 0.009 4 (1 to 10) 14 (7 to ne) 0.004
ICDSC, Intensive Care Delirium Screening Checklist
IQR, Interquartile range expressed as 25th to 75th percentile; the value of “ne” indicates the value could not be estimated from these
BP-value from comparison of proportion resolved between the two groups using the Pearson’s Chi-square test.
CP-value from comparison of time to first resolution between the two groups from Log-Rank test comparing Kaplan-Meier curves
Table 3 Time spent with each delirium symptom as a proportion of time study drug was administered
A, B
CDelirium symptom ever present
(Over course of study drug; N (%))
CTime spent with delirium symptom
(% of total days of study drug; median (IQR))
Delirium symptoms derived from ICDSC Quetiapine
(n = 14)
Placebo
(n = 15)
P-value Quetiapine
(n = 14)
Placebo
(n = 15)
CP-value
Agitation 6 (42.9) 7 (46.7) 0.83 0 (0 to 13) 14 (0 to 57) 0.17
Decreased level of consciousness 8 (57.1) 7 (46.7) 0.72 3 (0 to 50) 22 (7 to 29) 0.24
Inattention 13 (92.9) 15 (100) 0.29 47 (0 to 67) 78 (43 to 100) 0.03
Disorientation 13 (92.9) 12 (80) 0.59 35 (0 to 55) 52 (25 to 94) 0.27
Hallucinations/delusions 2 (14.3) 1 (6.7) 1.00 0 (0 to 17) 28 (0 to 43) 0.10
Hyperactivity 6 (42.9) 7 (46.7) 0.79 0 (0 to 20) 14 (0 to 57) 0.28
Hypoactivity 9 (64.3) 9 (60.0) 0.81 50 (17 to 83) 67 (22 to 88) 0.61
Inappropriate speech or mood 7 (77.8) 4 (16.0) 0.24 15 (0 to 44) 24 (0 to 60) 0.98
Sleep/wake cycle disturbances 9 (64.3) 10 (71.4) 0.82 58 (33 to 100) 83 (36 to 100) 0.69
Symptom fluctuation 11 (91.7) 14 (93.3) 0.52 47(19 to 67) 89 (33 to 100) 0.04
ICDSC, Intensive Care Delirium Screening Checklist
AAmong all patients and, therefore, regardless of whether each delirium symptom was present at baseline.
BTime spent was based on the number of 12 hour shifts where the symptom was present
CFor comparison of distributions between the two groups for time spent with delirium symptom using the Wilcoxon rank sums test
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quetiapine.
Few other reports of quetiapine use for delirium have
been published, and none were ICU-based studies. A
recent, randomized, double-blind study compared delir-
ium resolution with quetiapine or placebo treatment
among hospitalized (but not ICU) medical and surgical
patients and found the cognitive components recovered
83% faster in the quetiapine group, and noncognitive
scores recovered 57% faster than the placebo group [33].
A number of limitations of our study must be con-
sidered. First, patients were enrolled in the parent ran-
domized controlled study an average of six days after
ICU admission - nearly twice as long after ICU admis-
sion as when delirium often first presents [14]. Study
enrollment may have been delayed by our requirement
that delirium be an established diagnosis and treatment
with haloperidol initiated prior to consent and rando-
mization and that adequate gut function (for example,
tolerating enteral nutrition) be established. Although
not well characterized, it is possible that the individual
symptoms of delirium present in a patient with delir-
ium vary with time after ICU admission [26]. Second,
while a summary ICDSC score was documented for all
study patients, documentation of individual delirium
symptoms (from the ICDSC) was missing for 7 of the
36 patients in the parent stud y .I ti sp o s s i b l et h a tt h e
results of this secondary analysis may have been differ-
ent had all 36 patients been included although baseline
demographics and the time to first resolution of delir-
ium were similar between each post-hoc group (n = 14,
n = 15) and the corresponding groups in the parent
study (n = 18, n = 18). Some of the delirium symptoms
(for example, hallucinations) may have been detected
at too low of a frequency to allow for a valid analysis
of their time to resolution between the two study
groups.
We provide clinical information regarding the short-
term response of ICU symptoms, but did not evaluate
long-term follow-up after hospital discharge for these
patients. Whether long-term cognitive function may be
related to specific symptoms identified during the ICU
stay (as it is with delirium in general) remains unknown.
Since the study was initiated only in delirious patients,
the effect psychotropic drugs may have on subsyndro-
mal delirium remains unexplored. With multiple com-
parisons of 10 symptoms that were tested and the small
sample size, we chose to look for promising differences
which may serve as a foundation for future studies pow-
ered for this type of analysis. We also present the indivi-
dual unadjusted P-values for every comparison made, in
the spirit of maximal transparency and to fuel future
studies in this area.
Conclusions
Our exploratory analysis suggests that quetiapine
appears to resolve many ICU delirium symptoms faster
than the placebo, may result in less time with hallucina-
tions, inattention and symptom fluctuation and may
allow patients to spend more time at a desirable level of
consciousness. Future studies evaluating pharmacologic
therapy for ICU patients with delirium or subsyndromal
delirium may benefit from monitoring the resolution
and duration of individual delirium symptoms and long-
term cognitive function to determine whether the differ-
ent psychiatric symptoms of delirium are associated
with worse or better outcomes.
Key messages
￿ This study, the first to measure the response of
individual delirium symptoms to antipsychotic ther-
apy in the ICU, demonstrates that quetiapine use
may be associated with more rapid resolution of
many common ICU delirium symptoms compared
to placebo, resulting in less time affected by halluci-
nations, inattention, symptom fluctuation and an
undesirable level of consciousness.
￿ Psychomotor agitation and hyperactivity, a poten-
tial marker for lower mortality among delirious
patients but predictive of worse outcome among
patients not delirious, took longer to resolve with
quetiapine in this pilot study, but quetiapine appears
to lead to more time without agitation or depressed
consciousness.
￿ Future studies evaluating antipsychotics in ICU
patients with delirium should measure the resolution
of individual delirium symptoms.
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